Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, Marcelin AG; ROCnRAL ANRS-157 Study Group.
Soulié C, et al. Among authors: rodriguez c.
J Antimicrob Chemother. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280. Epub 2015 Sep 22.
J Antimicrob Chemother. 2015.
PMID: 26396157
Clinical Trial.